Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Mandel

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Pflugers Archiv : European Journal of Physiology|September 30, 2024
Unlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenaseMaximilian Molitor, Amelie Menge, Sebastian Mandel, et al.
Journal of Medicinal Chemistry|September 20, 2021
Design and Development of a Chemical Probe for Pseudokinase Ca<sup>2+</sup>/calmodulin-Dependent Ser/Thr KinaseNadine Russ, Martin Schröder, Benedict-Tilman Berger, et al.
ACS Chemical Biology|April 14, 2025
Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 InhibitorSebastian Mandel, Thomas Hanke, Sebastian Mathea, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|May 21, 2026
<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicitySimon Nannini, Céline Sieffert, Andrew McGown, et al.
Journal of Medicinal Chemistry|July 2, 2025
Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective InhibitorSebastian Mandel, Thomas Hanke, Niall Prendiville, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Pflugers Archiv : European Journal of Physiology|September 30, 2024
Unlocking the potential: unveiling tyrphostins with Michael-reactive cyanoacrylate motif as promising inhibitors of human 5-lipoxygenaseMaximilian Molitor, Amelie Menge, Sebastian Mandel, et al.
Journal of Medicinal Chemistry|September 20, 2021
Design and Development of a Chemical Probe for Pseudokinase Ca<sup>2+</sup>/calmodulin-Dependent Ser/Thr KinaseNadine Russ, Martin Schröder, Benedict-Tilman Berger, et al.
ACS Chemical Biology|April 14, 2025
Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 InhibitorSebastian Mandel, Thomas Hanke, Sebastian Mathea, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|May 21, 2026
<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicitySimon Nannini, Céline Sieffert, Andrew McGown, et al.
Journal of Medicinal Chemistry|July 2, 2025
Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective InhibitorSebastian Mandel, Thomas Hanke, Niall Prendiville, et al.
Pageof 1